About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5141084
Allelic
Composition
Mtss1Gt(CSC156)Byg/Mtss1Gt(CSC156)Byg
Genetic
Background
B6.129P2-Mtss1Gt(CSC156)Byg
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mtss1Gt(CSC156)Byg mutation (0 available); any Mtss1 mutation (119 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Mtss1Gt(CSC156)Byg/Mtss1Gt(CSC156)Byg cells display a distinct morphology and altered actin cytoskeleton reorganization

mortality/aging
• most mutants die between 14 and 24 months of age

neoplasm
• about 70% of mutants develop enlarged lymph notes or spleens infiltrated by abnormal lymphoid cells with vesicular nuclei, abundant cytoplasm and small nucleoli indicative of diffuse large B cell lymphoma; tumor cells are derived from CD5+ B-cells

hematopoietic system
• 81% of mutants have enlarged spleens
• marker analysis of early B-cell development indicates a 35% increase in the percentage of pre-B2 cells, a 22% and 73% reduction in the population of B cells expressing s-IgM in the bone marrow and spleen, respectively, and a reduction in the percentage of B cells with s-IgD, indicating aberrant B cell differentiation
• bone marrow shows a decrease in immature B cells
• 50% decrease in the percentage of CD19+ B cells in the spleen
• 20% increase in the percentage of B cells in the bone marrow and an even greater increase in the peripheral blood
• bone marrow shows a 35% increase in the percentage of pre-B2 cells
• white blood cell count is higher than in wild-type mice
• B cells do not undergo chemotaxis or morphological changes in response to the chemokine CXCL13

immune system
• 81% of mutants have enlarged spleens
• marker analysis of early B-cell development indicates a 35% increase in the percentage of pre-B2 cells, a 22% and 73% reduction in the population of B cells expressing s-IgM in the bone marrow and spleen, respectively, and a reduction in the percentage of B cells with s-IgD, indicating aberrant B cell differentiation
• bone marrow shows a decrease in immature B cells
• 50% decrease in the percentage of CD19+ B cells in the spleen
• 20% increase in the percentage of B cells in the bone marrow and an even greater increase in the peripheral blood
• bone marrow shows a 35% increase in the percentage of pre-B2 cells
• white blood cell count is higher than in wild-type mice
• B cells do not undergo chemotaxis or morphological changes in response to the chemokine CXCL13
• some mutants exhibit infiltrated leukocytes in the liver and the kidney, which contain a mixture of small T and B cells

liver/biliary system
• 56% of aged mutants exhibit hepatomegaly, with rough liver surfaces

cellular
• mouse embryonic fibroblasts exhibit smooth edges with few projections, reduced polarity, and altered actin cytoskeletal architecture compared with wild-type cells
• mouse embryonic fibroblasts (MEFs) exhibit impaired cell spreading during attachment compared with wild-type cells
• upon PDGF treatment, MEFs develop more prominent dorsal ruffles compared with wild-type cells
• MEFs exhibit 50% less internalization of transferrin compared with wild-type cells
• however, cell proliferation is normal
• mouse embryonic fibroblasts form poor focal adhesions compared with wild-type cells
• in 0.2% serum medium
• however, migration is restored by the addition of PDGF, EGF, or 10% serum

growth/size/body
• 56% of aged mutants exhibit hepatomegaly, with rough liver surfaces
• 81% of mutants have enlarged spleens

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
non-Hodgkin lymphoma DOID:0060060 OMIM:605027
J:186118


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
03/19/2024
MGI 6.23
The Jackson Laboratory